8T7A

Cryo-EM structure of RSV preF in complex with Fab 2.4K

Summary for 8T7A

• Entry DOI: 10.2210/pdb8t7a/pdb
• EMDB information: 41089
• Descriptor: Fusion glycoprotein F2, Fusion glycoprotein F1, 2.4K Fab Heavy Chain, ... (5 entities in total)
• Functional Keywords: complex, antibody, fusion protein, viral protein, viral protein-immune system complex, viral protein/immune system
• Biological source: Respiratory syncytial virus; More
• Total number of polymer chains: 12
• Total formula weight: 252473.78

Authors

McCool, R.S.,McLellan, J.S. (deposition date: 2023-06-20, release date: 2023-09-13, Last modification date: 2024-10-23)

Primary citation

McCool, R.S.,Musayev, M.,Bush, S.M.,Derrien-Colemyn, A.,Acreman, C.M.,Wrapp, D.,Ruckwardt, T.J.,Graham, B.S.,Mascola, J.R.,McLellan, J.S.
Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein elicits antibodies targeting a membrane-proximal epitope.
J.Virol., 97:e0092923-e0092923, 2023

PubMed Abstract: Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and pneumonia in infants, infecting all children by age 5. RSV also causes substantial morbidity and mortality in older adults, and a vaccine for older adults based on a prefusion-stabilized form of the viral F glycoprotein was recently approved by the FDA. Here, we investigate a set of antibodies that belong to the same public clonotype and were isolated from individuals vaccinated with a prefusion-stabilized RSV F protein. Our results reveal that these antibodies are highly potent and recognize a previously uncharacterized antigenic site on the prefusion F protein. Vaccination with prefusion RSV F proteins appears to boost the elicitation of these neutralizing antibodies, which are not commonly elicited by natural infection.

PubMed: 37737588
DOI: 10.1128/jvi.00929-23

Experimental method

ELECTRON MICROSCOPY (2.8 Å)